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Toxicokinetic studies undertaken within the National Toxicology Program are intended to aid the designi of toxicology and ogenicity studies, help interpret the results of toxicology and carcinogenicity studies with respectmo the rlati p beten toxic effects and exteral exposure, and define the parameters of d-wose, ibution m , an ei tt can be used in Commentary* Guidelines for toxicokinetic studies within the NTP relevant to the distribution of risk in exposed populations. The combination of dosimetry models with mechanistic data (e.g., mutagenicity, altered gene expression) can lead to more realistic biological models that would be useful in predicting site-specific dose responses and assessing human risk.
For most of the chemicals studied by the NTP, the mechanisms of toxicity or carcinogenicity are not known. In the absence of knowledge regarding the mechanism of action of a chemical, it is important to measure the effects of dose on chemical fate in test animals. To maximize the sensitivity of NTP bioassays, chemicals are often studied at doses that are far in excess of those that humans are likely to encounter. For some chemicals the effect of the dose on the test species is determined by measuring the plasma levels of the parent compound and metabolites over the dose range of interest. For other chemicals the critical toxic action may occur in the stomach, gastrointestinal tract, or liver prior to entering the systemic circulation. Even when the amount of parent compound absorbed into the systemic circulation is proportional to the dose administered, the metabolites that may actually account for toxicity associated with exposure to the parent compound may not be formed in or cleared from the target tissues in a manner proportional to dose. These parameters can be determined only through detailed studies of the dose-dependent metabolism and disposition of the chemical in question. For chemicals with low toxicity or which were not carcinogenic under the conditions of the bioassay, there may be little need for studies supporting the development of mechanistic models. However, negative toxicology studies and adequate disposition studies may provide valuable information on positive studies of structurally related chemicals. If the metabolic processes associated with a chemical differ between species, detailed modeling and comprehensive studies may be necessary. Chemicals of moderate or unknown toxicity (and/or equivocal carcinogenicity) that are important to public health may warrant comprehensive studies aimed at identifying the mechanisms of toxicity/carcinogenicity and associated pharmacokinetic parameters.
In the next section, we describe a general approach for a comprehensive toxicokinetic study and make suggestions of areas in which the design could be tailored for a specific chemical. Clewell and Andersen (1) describe the utility and advantages of using PBPK models in interpreting the results of toxicology experiments and in assessing human risk. In the last section, we describe a minimal approach that would be useful for the design of toxicology/carcinogenicity studies. It should be emphasized that the two approaches represent the extreme ends of a continuum of designs. Most studies will follow protocols that fall somewhere between these extremes. Study designers are free to eliminate elements from the comprehensive design that are inappropriate or unattainable for the chemical of interest or to add features to the minimal approach to answer specific questions of interest. The chemistry and toxicity of a specific compound may change the nature of the study conducted possible to obtain kinetic constants for the production and degradation of reactive intermediates in vitro. Although an in vitro study of the parent compound and a metabolite may ignore complicating interactions present in vivo, it presents an opportunity to measure production and detoxification rates needed for initial construction of the model. The appropriateness of this simplification of the biochemistry will be revealed during validation of the model. The range of substrate concentrations tested in vitro should include the range of concentrations expected in vivo, provided sufficiently sensitive analytical techniques are available. High substrate concentrations should also be tested in vitro to determine maximal rate ( V'ax ).
The PBPK model may need to include the kinetics of cofactor changes (e.g., glutathione, reduced nicotinamide adenine dinucleotide, reduced nicotinamide adenine dinucleotide phosphate) or competitive binding between metabolites and/or parent compound. Thus, the kinetics of these changes should also be measured in vitro. Use of human tissue samples provides an opportunity to compare metabolic activities between laboratory animals and humans. However, one should also be cautious in making quantitative comparisons because of the potential variability in the quality of normal human tissue.
Model validation. In the previous section, we described a study protocol design that could be used in the development of a PBPK model. It is at one end of the spectrum of possible study designs; at the opposite end is a minimal study protocol. Toxicologists are not compelled to make a choice between the two extremes of protocol design. The minimal protocol is a subset of the ideal protocol and does not require the use of radiolabeled compound. This study design is likely to answer only questions 1), 4), and 5) from the list presented at the beginning of the previous section and would greatly help in the design and interpretation of the animal toxicity studies. However, the inclusion of some components of the comprehensive protocol in the minimal protocol (e.g., sampling excreta in addition to blood or measuring partition coefficients) would further improve the utility of the latter protocol in interpreting the results of a toxicology study and in risk assessment. Both study designs share the following common features.
Animals. The same strain and species as in the toxicology studies should be used in the TK studies. Initial studies may involve one sex of one species (e.g., male rats). Young healthy adults (10-12 weeks of age, matched for body weight) should be used, except for studies examining the effect of age on the ADME of a chemical. Sufficient animals should be included in the TK study design to guarantee a minimum of three data samples per time point of analysis.
Chemical Radiolabeled chemical is not required although it can be used if available.
Route of exposure. The same route in the toxicology study or the most common route of human exposure should be used, in addition to the iv route for estimation of absorption.
Dose levels. For non-iv routes of exposure, blood samples (plasma or serum) should be collected at several time points (10-12) sufficient to characterize the chemical concentration in plasma or other tissues versus time profiles. Sampling interval and times will depend on the rate of absorption and clearance of the chemical.
Analyses. Blood/plasma samples should be assayed for the administered compound. For some chemicals (e.g., esters that are rapidly hydrolyzed), a major metabolite must be measured instead of the parent chemical.
This design is similar to several protocols already in use at the National Institute of Environmental Health Sciences. The minimal design almost completely ignores the issue of metabolism and identification of the toxic agent (if presumed different than the parent chemical). This design is purposely modest in scale. In most cases, parameters obtained from disposition or toxicokinetic studies in a single sex of a single species provide some indication of the processes involved. If differences in LD50 or health effects between species or sexes are known, it may be necessary to include animals of more than one species or of both sexes. In general, a chemical that is readily absorbed by the male rat will be readily absorbed by the female and by mice and by humans, though the rates will not be identical. Additional a priori knowledge about a chemical could further change this proposed design. For instance, study of a chemical known to undergo significant enterohepatic recirculation may call for the use of bile duct-cannulated animals.
